TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE

凭借PathogenDx的解决方案（DetectX-Rv），在接下来的四个月里，我们将在不增加实验室占地面积的情况下，为全国提供25倍的测试能力，而不会增加无尽的测试系统线，这些测试系统会立即贬值，坚持所需的准确测试水平，以及可以<s:2>“灵活<e:2>”满足不同尺寸SBS板市场需求的解决方案。我们的建议是在相同的实际测试基板上将测试容量翻两倍，在不到4个月的时间内将相同的SBS板从12个井阵列滑动优化到96个井，最终优化到384个井格式。执行此策略将每月交付415万个测试，每次测试可节省55%和70%的成本。相比之下，如果使用qRT-PCR技术部署相同的容量，RaDx的资本支出将增加5倍，每次测试成本将增加3倍。

With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing  lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates.  What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months.   Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.